ATYPICAL CHRONIC MYELOID LEUKEMIA
Clinical trials for ATYPICAL CHRONIC MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new ATYPICAL CHRONIC MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for ATYPICAL CHRONIC MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can pressurized oxygen boost stem cell transplants?
Disease control Recruiting nowThis early-phase study tests whether adding hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) to standard stem cell transplant preparation is safe and helps recovery. It involves 24 adults with various blood cancers, such as leukemia and myelofibrosis. Th…
Matched conditions: ATYPICAL CHRONIC MYELOID LEUKEMIA
Phase: EARLY_PHASE1 • Sponsor: Omar Aljitawi • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo aims to shrink Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new antibody called axatilimab, given with or without the chemotherapy drug azacitidine, for people with advanced myeloproliferative neoplasms (MPN), MPN/MDS overlap, or high-risk chronic myelomonocytic leukemia (CMML). The goal is to find the safest dose and s…
Matched conditions: ATYPICAL CHRONIC MYELOID LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug cocktail aims to tame deadly transplant side effect
Disease control Recruiting nowThis phase 2 trial tests whether adding two drugs, ruxolitinib and abatacept, to standard transplant care can prevent graft-versus-host disease (GVHD) in 60 patients with high-risk myeloid cancers like AML and MDS. Participants receive a stem cell transplant from a partially matc…
Matched conditions: ATYPICAL CHRONIC MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: St. Petersburg State Pavlov Medical University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Scientists launch 20-Year MDS watch to unlock disease secrets
Knowledge-focused Recruiting nowThis study follows people with myelodysplastic syndromes (MDS) for up to 20 years to understand how the disease changes over time. Researchers will collect blood, bone marrow, and other samples from 1,100 participants, including healthy donors. The goal is to learn more about MDS…
Matched conditions: ATYPICAL CHRONIC MYELOID LEUKEMIA
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC